TRENDING KEYWORDS
Pfizer (PFE, $44.25) said Covid vaccine late-stage trial in children 5-11 showed favorable results
Pfizer Inc. said that results from its Covid-19 vaccine’s late-stage trial involving young children showed a "favorable safety profile and robust neutralizing antibody responses."
The pharmaceutical company said that a 10 µg dose given to children between the ages of 5 and 11 (which is around a third of that given to older children and young adults in similar testing) produced comparable results in generating antibodies that can protect against virus.
Pfizer expects to submit the trial data to the U.S. Food & Drug Administration, as well as the European Medicines Agency, "as soon as possible.”
The drugmaker also mentioned that data from trials involving children under the age of 5 will be available later this year.
Momentum Indicator for PFE turns positive, indicating new upward trend
PFE saw its Momentum Indicator move above the 0 level on May 12, 2022. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned positive. In 50 of the 82 cases, the stock moved higher in the following days. The odds of a move higher are at 61%.
Current price $53.79 crossed the support line at $48.83 and is trading between $53.84 resistance and $48.83 support lines. Throughout the month of 04/25/22 - 05/25/22, the price experienced a +11% Uptrend. During the week of 05/18/22 - 05/25/22, the stock enjoyed a +7% Uptrend growth.
The Moving Average Convergence Divergence (MACD) for PFE just turned positive on May 11, 2022. Looking at past instances where PFE's MACD turned positive, the stock continued to rise in 24 of 46 cases over the following month. The odds of a continued upward trend are 52%.
PFE moved above its 50-day Moving Average on May 20, 2022 date and that indicates a change from a downward trend to an upward trend.
The 10-day Moving Average for PFE crossed bullishly above the 50-day moving average on May 24, 2022. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 58%.
Following a +1.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in 167 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 53%.
The Aroon Indicator entered an Uptrend today. In 159 of 343 cases where PFE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 46%.
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Indicator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 48%.
PFE broke above its upper Bollinger Band on May 20, 2022. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Tickeron has a positive outlook on this ticker and predicts a further increase by more than 4.00% within the next month with a likelihood of 68%. During the last month, the daily ratio of advancing to declining volumes was 2.15 to 1.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.656) is normal, around the industry mean (7.039). P/E Ratio (12.092) is within average values for comparable stocks, (85.796). Projected Growth (PEG Ratio) (1.110) is also within normal values, averaging (3.227). Dividend Yield (0.029) settles around the average of (0.025) among similar stocks. P/S Ratio (3.331) is also within normal values, averaging (3.890).
The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 33 (best 1 - 100 worst), indicating outstanding price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 77 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
The average market capitalization across the Pharmaceuticals: Major Industry is 81.2B. The market cap for tickers in the group ranges from 226K to 477.3B. JNJ holds the highest valuation in this group at 477.3B. The lowest valued company is NEWG at 226K.
The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 1.31%. For the same Industry, the average monthly price growth was -0.33%, and the average quarterly price growth was -2.81%. RHHBF experienced the highest price growth at 8.94%, while CRXT experienced the biggest fall at -14.44%.
- 5/17/22 6:52 AM: Pfizer (PFE, $50.67) was a top weekly gainer, with a +5.02% jump
- 4/20/22 8:58 AM: Pfizer (PFE, $50.18) was a top loser this week, declining -5.52%
- 4/12/22 7:11 AM: Pfizer (PFE, $53.93) was a top weekly gainer, with a +5.87% jump
The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 5.39%. For the same stocks of the Industry, the average monthly volume growth was -5.99% and the average quarterly volume growth was 22.61%
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Stocks in the group have a Positive Outlook today, backed by the MACD Indicator. Tickeron has a positive outlook on this group and predicts a further increase by more than 4.00% within the next month with a likelihood of 57%. During the last month, the daily ratio of advancing to declining volumes was 1.39 to 1.
5 stocks in the group of tickers confirmed the positive outlook based on the BollingerBands indicator with average odds of 65%.
The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Merck & Co (NYSE:MRK), Bristol-Myers Squibb Co (NYSE:BMY).
The average market capitalization across the group is 117.4B. The market cap for tickers in the group ranges from 11.4M to 291.7B. LLY holds the highest valuation in this group at 291.7B. The lowest valued company is YMTX at 11.4M.
The average weekly price growth across all stocks in the group was 0.24%. For the same group, the average monthly price growth was -3.5%, and the average quarterly price growth was -8.6%. SNY experienced the highest price growth at 6.6%, while BTX experienced the biggest fall at -15.85%.
- 5/24/22 7:00 AM: Sanofi ADS (SNY, $55.43) was a top weekly gainer, with a +5.46% jump
- 5/17/22 6:52 AM: Novartis AG (NVS, $87.81) was a top weekly gainer, with a +5.19% jump
- 5/12/22 5:38 AM: GlaxoSmithKline (GSK, $42.53) was a top loser this week, declining -5.82%
The average weekly volume growth across all stocks in the group was 31.62%. For the same stocks of the group, the average monthly volume growth was 28.59% and the average quarterly volume growth was 36.45%
- 3/25/22 6:03 AM: The volume for Yumanity Therapeutics stock increased for one day, resulting in a record-breaking daily growth of 661% of the 65-Day Volume Moving Average
- 3/23/22 4:46 AM: The volume for Yumanity Therapeutics stock increased for one day, resulting in a record-breaking daily growth of 268% of the 65-Day Volume Moving Average
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Latest blogs by Sarah Patel
Top Blogs
